Challenges and Opportunities in Gene Delivery - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 73

[19] Inovio Pharmaceuticals, Inovio Product Pipeline: PSMA: Prostate cancers. http:// www
.inovio.com/products/psma_prostate.html. [accessed on 04.01.10].
[20] Visiongain. Top companies and products in the RNA/DNA therapy-products market
forecasts: the challenge of turning technology into therapy. http:// www.the-infoshop.com/
report/kt55538-therapy-prod.html ; 2007 [accessed on 03.02.10].
[21] Anderson WF. Human gene therapy. Nature 1998;392:25-30.
[22] Poutona CW, Seymour LW. Key issues in non-viral gene delivery. Adv Drug Delivery
Rev 2001;46:187-203.
[23] Danialou G, Comtois AS, Matecki S, Nalbantoglu J, Karpati G, Gilbert R, et al.
Optimization of regional intraarterial naked DNA-mediated transgene delivery to skeletal
muscles in a large animal model. Mol Ther 2005;11:257-66.
[24] Yazawa H, Murakami T, Li HM, Back T, Kurosaka K, Suzuki Y, et al. Hydrodynamics-
based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively sup-
presses the growth of pre-existing tumors. Cancer Gene Ther 2006;13:993-1001.
[25] Hickman MA, Malone RW, Lehmann BK, Sih TR, Knoell D, Szoka FC, et al. Gene
expression following direct injection of DNA into liver. Hum Gene Ther 1994;5:
1477-83.
[26] Budker V, Zhang G, Knechtle S, Wolff JA. Naked DNA delivered intraportally expresses
efficiently in hepatocytes. Gene Ther 1996;3:593-8.
[27] Sawamura D, Abe R, Goto M, Akiyama M, Hemmi H, Akira S, et al. Direct injection
of plasmid DNA into the skin induces dermatitis by activation of monocytes through
toll-like receptor 9. J Gene Med 2005;7:664-71.
[28] Choate KA, Khavari PA. Direct cutaneous gene delivery in a human genetic skin disease.
Hum Gene Ther 1997;8:1659-65.
[29] Meyer KB, Thompson MM, Levy MY, Barron LG, Szoka FC. Intratracheal gene delivery
to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics.
Gene Ther 1995;2:450-60.
[30] Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic
science to clinical application. J Pathol 2006;208:299-318.
[31] Tachibana R, Harashima H, Ide N, Ukitsu S, Ohta Y, Suzuki N, et al. Quantitative analy-
sis of correlation between number of nuclear plasmids and gene expression activity after
transfection with cationic liposomes. Pharm Res 2002;19:377-81.
[32] James MB, Giorgio TD. Nuclear-associated plasmid, but not cell-associated plasmid,
is correlated with transgene expression in cultured mammalian cells. Mol Ther 2000;1:
339-46.
[33] Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug
Delivery Rev 2001;53:135-54.
[34] Penacho N, Filipe A, Simoes SC, Pedroso LM. Transferrin-associated lipoplexes as gene
delivery systems: Relevance of mode of preparation and biophysical properties. J Membr
Biol 2008;221:141-52.
[35] Rui Y, Wang S, Low PS, Thompson DH. Diplasmenylcholine—folate liposomes: an effi-
cient vehicle for intracellular drug delivery. J Am Chem Soc 1998;120:11213-18.
[36] Zanta MA, Valladier PB, Behr JP. Gene delivery: a single nuclear localization signal pep-
tide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA 1999;96:9196.
[37] Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug
Delivery Rev 2000;44:119-34.
[38] Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH, et al. A clinical
inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic
fibrosis. Hum Gene Ther 2001;12:751-61.